KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Preferred Stock Liabilities (2018 - 2019)

Vir Biotechnology's Preferred Stock Liabilities history spans 2 years, with the latest figure at $636.6 million for Q3 2019.

  • For Q3 2019, Preferred Stock Liabilities rose 105.93% year-over-year to $636.6 million; the TTM value through Sep 2019 reached $636.6 million, up 105.93%, while the annual FY2018 figure was $309.1 million, 5.68% up from the prior year.
  • Preferred Stock Liabilities for Q3 2019 was $636.6 million at Vir Biotechnology, roughly flat from $636.6 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $636.6 million in Q2 2019 and bottomed at $309.1 million in Q3 2018.